Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2017

01-11-2017 | Letter to the Editor

Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations

Authors: Mingshan Niu, Yangling Shen, Jialei Qi, Xuejiao Liu, Wei Sang, Qingyun Wu, Jiang Cao, Wei Chen, Yao Yao, Kailin Xu

Published in: Annals of Hematology | Issue 11/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Zeng C, Yu X, Lai J, Yang L, Chen S, Li Y (2015) Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia. J Hematol Oncol 8:126CrossRefPubMedPubMedCentral
2.
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121CrossRefPubMed
3.
Zhu HH, Qin YZ, Huang XJ (2014) Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med 370:1864–1866CrossRefPubMed
4.
Lou Y, Ma Y, Sun J, Ye X, Pan H, Wang Y et al (2015) Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients. Ann Hematol 94:1829–1837CrossRefPubMed
5.
Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX et al (2013) Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 31:4215–4221CrossRefPubMed
6.
Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10:547–555CrossRefPubMed
7.
Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S et al (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18:88–98CrossRefPubMed
8.
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA et al (2013) Acute myeloid leukemia, version 2.2013. J Natl Compr Cancer Netw 11:1047–1055CrossRef
9.
Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al (2012) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119:1599–1606CrossRefPubMed
10.
Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J et al (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23:4110–4116CrossRefPubMed
Metadata
Title
Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations
Authors
Mingshan Niu
Yangling Shen
Jialei Qi
Xuejiao Liu
Wei Sang
Qingyun Wu
Jiang Cao
Wei Chen
Yao Yao
Kailin Xu
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3093-8

Other articles of this Issue 11/2017

Annals of Hematology 11/2017 Go to the issue

Original Article

Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study

Original Article

A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis

Original Article

Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly

Original Article

A cross-sectional study on late taste disorders in survivors of allogeneic hematopoietic cell transplantation

Original Article

Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia

Original Article

Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits